vs
NEOGENOMICS INC（NEO）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是NEOGENOMICS INC的1.2倍（$219.9M vs $186.7M），Orthofix Medical Inc.净利率更高（-1.0% vs -57.9%，领先56.8%），NEOGENOMICS INC同比增速更快（11.1% vs 2.0%），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs 6.5%）
新基因组公司（NeoGenomics）是美国一家经CLIA认证的临床实验室企业，提供药企服务与信息服务，专注于癌症基因诊断检测，旗下检测服务涵盖细胞遗传学、荧光原位杂交（FISH）、流式细胞术、免疫组化、解剖病理学及分子遗传学等多个领域，为肿瘤相关诊断提供专业支持。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
NEO vs OFIX — 直观对比
营收规模更大
OFIX
是对方的1.2倍
$186.7M
营收增速更快
NEO
高出9.1%
2.0%
净利率更高
OFIX
高出56.8%
-57.9%
两年增速更快
OFIX
近两年复合增速
6.5%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $186.7M | $219.9M |
| 净利润 | $-108.0M | $-2.2M |
| 毛利率 | 43.3% | 71.1% |
| 营业利润率 | 46.9% | 0.2% |
| 净利率 | -57.9% | -1.0% |
| 营收同比 | 11.1% | 2.0% |
| 净利润同比 | 42.0% | 92.4% |
| 每股收益（稀释后） | $-0.13 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NEOOFIX
| Q1 26 | $186.7M | — | ||
| Q4 25 | $190.2M | $219.9M | ||
| Q3 25 | $187.8M | $205.6M | ||
| Q2 25 | $181.3M | $203.1M | ||
| Q1 25 | $168.0M | $193.6M | ||
| Q4 24 | $172.0M | $215.7M | ||
| Q3 24 | $167.8M | $196.6M | ||
| Q2 24 | $164.5M | $198.6M |
净利润NEOOFIX
| Q1 26 | $-108.0M | — | ||
| Q4 25 | — | $-2.2M | ||
| Q3 25 | $-27.1M | $-22.8M | ||
| Q2 25 | $-45.1M | $-14.1M | ||
| Q1 25 | $-25.9M | $-53.1M | ||
| Q4 24 | — | $-29.1M | ||
| Q3 24 | $-17.7M | $-27.4M | ||
| Q2 24 | $-18.6M | $-33.4M |
毛利率NEOOFIX
| Q1 26 | 43.3% | — | ||
| Q4 25 | 43.8% | 71.1% | ||
| Q3 25 | 42.8% | 72.2% | ||
| Q2 25 | 42.6% | 68.7% | ||
| Q1 25 | 43.6% | 62.8% | ||
| Q4 24 | 44.9% | 69.0% | ||
| Q3 24 | 44.6% | 68.7% | ||
| Q2 24 | 44.1% | 67.8% |
营业利润率NEOOFIX
| Q1 26 | 46.9% | — | ||
| Q4 25 | -7.1% | 0.2% | ||
| Q3 25 | -14.4% | -8.3% | ||
| Q2 25 | -26.3% | -7.9% | ||
| Q1 25 | -16.6% | -25.2% | ||
| Q4 24 | -10.7% | -5.3% | ||
| Q3 24 | -12.6% | -9.6% | ||
| Q2 24 | -13.3% | -12.5% |
净利率NEOOFIX
| Q1 26 | -57.9% | — | ||
| Q4 25 | — | -1.0% | ||
| Q3 25 | -14.4% | -11.1% | ||
| Q2 25 | -24.9% | -6.9% | ||
| Q1 25 | -15.4% | -27.4% | ||
| Q4 24 | — | -13.5% | ||
| Q3 24 | -10.5% | -13.9% | ||
| Q2 24 | -11.3% | -16.8% |
每股收益（稀释后）NEOOFIX
| Q1 26 | $-0.13 | — | ||
| Q4 25 | — | $-0.05 | ||
| Q3 25 | — | $-0.57 | ||
| Q2 25 | — | $-0.36 | ||
| Q1 25 | — | $-1.35 | ||
| Q4 24 | — | $-0.76 | ||
| Q3 24 | — | $-0.71 | ||
| Q2 24 | — | $-0.88 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $146.1M | $82.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $828.8M | $450.0M |
| 总资产 | $1.3B | $850.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资NEOOFIX
| Q1 26 | $146.1M | — | ||
| Q4 25 | $159.6M | $82.0M | ||
| Q3 25 | $164.1M | $62.9M | ||
| Q2 25 | $154.7M | $65.6M | ||
| Q1 25 | $346.2M | $58.0M | ||
| Q4 24 | $367.0M | $83.2M | ||
| Q3 24 | $362.0M | $30.1M | ||
| Q2 24 | $355.1M | $26.4M |
总债务NEOOFIX
| Q1 26 | — | — | ||
| Q4 25 | $341.9M | — | ||
| Q3 25 | — | $157.2M | ||
| Q2 25 | — | $157.0M | ||
| Q1 25 | — | $156.9M | ||
| Q4 24 | $541.1M | $157.0M | ||
| Q3 24 | — | $118.5M | ||
| Q2 24 | — | $118.0M |
股东权益NEOOFIX
| Q1 26 | $828.8M | — | ||
| Q4 25 | $836.6M | $450.0M | ||
| Q3 25 | $838.3M | $442.5M | ||
| Q2 25 | $854.0M | $458.3M | ||
| Q1 25 | $888.3M | $458.3M | ||
| Q4 24 | $902.3M | $503.1M | ||
| Q3 24 | $908.2M | $525.9M | ||
| Q2 24 | $915.9M | $546.0M |
总资产NEOOFIX
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.4B | $850.6M | ||
| Q3 25 | $1.4B | $832.6M | ||
| Q2 25 | $1.4B | $837.2M | ||
| Q1 25 | $1.6B | $823.1M | ||
| Q4 24 | $1.6B | $893.3M | ||
| Q3 24 | $1.6B | $867.9M | ||
| Q2 24 | $1.6B | $882.0M |
负债/权益比NEOOFIX
| Q1 26 | — | — | ||
| Q4 25 | 0.41× | — | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.34× | ||
| Q4 24 | 0.60× | 0.31× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.22× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-8.1M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | — | $16.8M |
| 自由现金流率自由现金流/营收 | — | 7.6% |
| 资本支出强度资本支出/营收 | — | 4.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-1.3M |
8季度趋势，按日历期对齐
经营现金流NEOOFIX
| Q1 26 | $-8.1M | — | ||
| Q4 25 | $1.3M | $27.7M | ||
| Q3 25 | $8.9M | $12.4M | ||
| Q2 25 | $20.3M | $11.6M | ||
| Q1 25 | $-25.3M | $-18.4M | ||
| Q4 24 | $9.8M | $23.7M | ||
| Q3 24 | $9.2M | $11.7M | ||
| Q2 24 | $13.9M | $9.0M |
自由现金流NEOOFIX
| Q1 26 | — | — | ||
| Q4 25 | $-6.5M | $16.8M | ||
| Q3 25 | $570.0K | $2.5M | ||
| Q2 25 | $14.0M | $4.5M | ||
| Q1 25 | $-29.8M | $-25.1M | ||
| Q4 24 | $-1.8M | $15.2M | ||
| Q3 24 | $-1.6M | $6.3M | ||
| Q2 24 | $814.0K | $-360.0K |
自由现金流率NEOOFIX
| Q1 26 | — | — | ||
| Q4 25 | -3.4% | 7.6% | ||
| Q3 25 | 0.3% | 1.2% | ||
| Q2 25 | 7.7% | 2.2% | ||
| Q1 25 | -17.8% | -13.0% | ||
| Q4 24 | -1.0% | 7.0% | ||
| Q3 24 | -0.9% | 3.2% | ||
| Q2 24 | 0.5% | -0.2% |
资本支出强度NEOOFIX
| Q1 26 | — | — | ||
| Q4 25 | 4.1% | 4.9% | ||
| Q3 25 | 4.4% | 4.8% | ||
| Q2 25 | 3.5% | 3.5% | ||
| Q1 25 | 2.7% | 3.5% | ||
| Q4 24 | 6.7% | 4.0% | ||
| Q3 24 | 6.4% | 2.7% | ||
| Q2 24 | 8.0% | 4.7% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NEO
暂无分部数据
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
